Sanofi (SNY) Stock Forecast, Price Target & Predictions
SNY Stock Forecast
Sanofi stock forecast is as follows: an average price target of $57.36 (represents a 0.40% upside from SNY’s last price of $57.13) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
SNY Price Target
The average price target for Sanofi (SNY) is $57.36 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $64.00 to $48.07. This represents a potential 0.40% upside from SNY's last price of $57.13.
SNY Analyst Ratings
According to 5 Wall Street analysts, Sanofi's rating consensus is 'Buy'. The analyst rating breakdown for SNY stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 0 'Hold' (0.00%), 1 'Sell' (20.00%), and 0 'Strong Sell' (0.00%).
Sanofi Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 10, 2024 | Luisa Hector | Berenberg Bank | $64.00 | $58.51 | 9.38% | 12.03% |
| Jul 26, 2024 | Jasper Hellweg | Argus Research | $60.00 | $52.53 | 14.21% | 5.02% |
| Apr 03, 2024 | Jasper Hellweg | Argus Research | $55.00 | $48.00 | 14.58% | -3.73% |
| Dec 21, 2022 | Iain Simpson | Barclays | $48.07 | $48.17 | -0.21% | -15.86% |
The latest Sanofi stock forecast, released on Sep 10, 2024 by Luisa Hector from Berenberg Bank, set a price target of $64.00, which represents a 9.38% increase from the stock price at the time of the forecast ($58.51), and a 12.03% increase from SNY last price ($57.13).
Sanofi Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 3 |
| Avg Price Target | $64.00 | $62.00 | $59.67 |
| Last Closing Price | $57.13 | $57.13 | $57.13 |
| Upside/Downside | 12.03% | 8.52% | 4.45% |
In the current month, the average price target of Sanofi stock is $64.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 12.03% increase as opposed to Sanofi's last price of $57.13. This month's average price target is up 3.23% compared to last quarter, and up 7.26% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 29, 2024 | Deutsche Bank | Sell | Sell | Hold |
| Jul 11, 2024 | Guggenheim | Buy | Buy | Hold |
| Jul 02, 2024 | Jefferies | Buy | Buy | Hold |
| Aug 18, 2022 | Oppenheimer | Outperform | Outperform | Hold |
| Aug 12, 2022 | Deutsche Bank | - | Hold | Upgrade |
| Jun 07, 2022 | UBS | Buy | Buy | Hold |
Sanofi's last stock rating was published by Deutsche Bank on Jul 29, 2024. The company gave SNY a "Sell" rating, the same as its previous rate.
Sanofi Financial Forecast
Sanofi Revenue Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Dec 17 | Sep 17 | Jun 17 | Mar 17 | Dec 16 | Sep 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $10.86B | $11.46B | $13.14B | $10.74B | $10.05B | $10.41B | $10.83B | $9.04B | $9.74B | $9.88B | $8.44B | $10.02B | $9.92B | $8.98B | $8.71B | $9.33B | $9.74B | $8.48B | $8.98B | $9.39B | $8.93B | $8.90B | $9.18B | $9.29B |
| Avg Forecast | $12.92B | $10.85B | $10.62B | $11.93B | $12.48B | $12.75B | $11.03B | $12.73B | $13.28B | $11.59B | $10.03B | $11.57B | $12.07B | $10.54B | $9.17B | $10.06B | $7.72B | $9.29B | $9.92B | $9.49B | $8.02B | $9.61B | $8.51B | $8.25B | $10.01B | $9.00B | $9.17B | $8.26B | $9.04B | $6.97B |
| High Forecast | $13.05B | $11.09B | $10.86B | $12.33B | $12.69B | $15.30B | $13.24B | $15.28B | $15.94B | $13.91B | $12.03B | $13.89B | $14.49B | $12.64B | $11.01B | $12.08B | $9.27B | $11.15B | $11.91B | $11.39B | $9.62B | $11.54B | $10.22B | $9.89B | $12.01B | $10.80B | $11.00B | $9.91B | $10.85B | $8.37B |
| Low Forecast | $12.64B | $10.63B | $10.40B | $11.58B | $12.25B | $10.20B | $8.82B | $10.19B | $10.62B | $9.27B | $8.02B | $9.26B | $9.66B | $8.43B | $7.34B | $8.05B | $6.18B | $7.43B | $7.94B | $7.59B | $6.41B | $7.69B | $6.81B | $6.60B | $8.01B | $7.20B | $7.33B | $6.61B | $7.23B | $5.58B |
| # Analysts | 4 | 2 | 1 | 3 | 5 | 19 | 16 | 20 | 19 | 14 | 9 | 18 | 19 | 10 | 10 | 16 | 16 | 7 | 14 | 17 | 14 | 12 | 19 | 12 | 18 | 12 | 20 | 9 | 12 | 9 |
| Surprise % | - | - | - | - | - | - | 0.98% | 0.90% | 0.99% | 0.93% | 1.00% | 0.90% | 0.90% | 0.86% | 1.06% | 0.98% | 1.09% | 1.08% | 1.00% | 0.95% | 1.09% | 0.97% | 1.14% | 1.03% | 0.90% | 1.04% | 0.97% | 1.08% | 1.02% | 1.33% |
Sanofi's average Quarter revenue forecast for Jun 23 based on 19 analysts is $12.75B, with a low forecast of $10.20B, and a high forecast of $15.30B. SNY's average Quarter revenue forecast represents a 17.35% increase compared to the company's last Quarter revenue of $10.86B (Mar 23).
Sanofi EBITDA Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Dec 17 | Sep 17 | Jun 17 | Mar 17 | Dec 16 | Sep 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 2 | 1 | 3 | 5 | 19 | 16 | 20 | 19 | 14 | 9 | 18 | 19 | 10 | 10 | 16 | 16 | 7 | 14 | 17 | 14 | 12 | 19 | 12 | 18 | 12 | 20 | 9 | 12 | 9 |
| EBITDA | - | - | - | - | - | - | $3.38B | $2.71B | $5.16B | $2.64B | $3.03B | $1.91B | $3.40B | $1.99B | $1.91B | $2.35B | $8.68B | $449.00M | $2.66B | $368.00M | $2.06B | $748.00M | $3.37B | $1.52B | $1.37B | $2.52B | $1.91B | $6.65B | $1.99B | $2.80B |
| Avg Forecast | $4.34B | $3.65B | $2.93B | $4.01B | $4.20B | $2.28B | $2.66B | $2.02B | $3.39B | $2.07B | $2.42B | $1.84B | $3.08B | $1.89B | $1.79B | $2.39B | $2.18B | $416.46M | $2.66B | $389.03M | $1.89B | $771.02M | $2.94B | $1.48B | $1.53B | $2.41B | $1.96B | $6.18B | $1.96B | $2.10B |
| High Forecast | $4.39B | $3.73B | $3.51B | $4.15B | $4.27B | $2.74B | $3.19B | $2.42B | $4.06B | $2.49B | $2.90B | $2.20B | $3.69B | $2.26B | $2.15B | $2.87B | $2.61B | $499.76M | $3.20B | $466.83M | $2.27B | $925.22M | $3.53B | $1.77B | $1.83B | $2.89B | $2.35B | $7.41B | $2.36B | $2.52B |
| Low Forecast | $4.25B | $3.57B | $2.34B | $3.90B | $4.12B | $1.83B | $2.13B | $1.62B | $2.71B | $1.66B | $1.93B | $1.47B | $2.46B | $1.51B | $1.44B | $1.92B | $1.74B | $333.17M | $2.13B | $311.22M | $1.51B | $616.81M | $2.35B | $1.18B | $1.22B | $1.93B | $1.56B | $4.94B | $1.57B | $1.68B |
| Surprise % | - | - | - | - | - | - | 1.27% | 1.34% | 1.52% | 1.27% | 1.25% | 1.04% | 1.10% | 1.05% | 1.06% | 0.98% | 3.99% | 1.08% | 1.00% | 0.95% | 1.09% | 0.97% | 1.14% | 1.03% | 0.90% | 1.04% | 0.97% | 1.08% | 1.02% | 1.33% |
19 analysts predict SNY's average Quarter EBITDA for Jun 23 to be $2.28B, with a high of $2.74B and a low of $1.83B. This is -32.56% lower than Sanofi's previous annual EBITDA (Mar 23) of $3.38B.
Sanofi Net Income Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Dec 17 | Sep 17 | Jun 17 | Mar 17 | Dec 16 | Sep 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 2 | 1 | 3 | 5 | 19 | 16 | 20 | 19 | 14 | 9 | 18 | 19 | 10 | 10 | 16 | 16 | 7 | 14 | 17 | 14 | 12 | 19 | 12 | 18 | 12 | 20 | 9 | 12 | 9 |
| Net Income | - | - | - | - | - | - | $2.00B | $1.46B | $2.08B | $1.18B | $2.01B | $1.12B | $2.32B | $1.21B | $1.08B | $1.95B | $7.60B | $-10.00M | $1.77B | $-87.00M | $1.14B | $254.00M | $2.27B | $762.00M | $129.00M | $1.57B | $1.04B | $5.70B | $790.00M | $1.67B |
| Avg Forecast | $3.12B | $2.08B | $2.04B | $2.15B | $3.25B | $1.39B | $1.86B | $1.19B | $2.31B | $1.26B | $1.69B | $1.09B | $2.10B | $1.15B | $1.02B | $1.99B | $6.90B | $-9.28M | $1.77B | $-91.97M | $1.05B | $261.82M | $1.99B | $740.83M | $143.74M | $1.50B | $1.06B | $5.29B | $778.03M | $1.26B |
| High Forecast | $3.26B | $2.14B | $2.45B | $2.43B | $4.08B | $1.67B | $2.23B | $1.43B | $2.77B | $1.52B | $2.03B | $1.30B | $2.52B | $1.38B | $1.22B | $2.39B | $8.28B | $-7.42M | $2.12B | $-73.58M | $1.26B | $314.18M | $2.38B | $889.00M | $172.49M | $1.80B | $1.28B | $6.35B | $933.64M | $1.51B |
| Low Forecast | $2.94B | $2.02B | $1.63B | $2.04B | $1.97B | $1.11B | $1.49B | $955.99M | $1.85B | $1.01B | $1.35B | $869.08M | $1.68B | $918.99M | $814.67M | $1.59B | $5.52B | $-11.13M | $1.41B | $-110.37M | $836.83M | $209.45M | $1.59B | $592.67M | $114.99M | $1.20B | $851.43M | $4.24B | $622.42M | $1.00B |
| Surprise % | - | - | - | - | - | - | 1.07% | 1.22% | 0.90% | 0.93% | 1.19% | 1.03% | 1.10% | 1.05% | 1.06% | 0.98% | 1.10% | 1.08% | 1.00% | 0.95% | 1.09% | 0.97% | 1.14% | 1.03% | 0.90% | 1.04% | 0.97% | 1.08% | 1.02% | 1.33% |
Sanofi's average Quarter net income forecast for Jun 23 is $1.39B, with a range of $1.11B to $1.67B. SNY's average Quarter net income forecast represents a -30.33% decrease compared to the company's last Quarter net income of $2.00B (Mar 23).
Sanofi SG&A Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Dec 17 | Sep 17 | Jun 17 | Mar 17 | Dec 16 | Sep 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 2 | 1 | 3 | 5 | 19 | 16 | 20 | 19 | 14 | 9 | 18 | 19 | 10 | 10 | 16 | 16 | 7 | 14 | 17 | 14 | 12 | 19 | 12 | 18 | 12 | 20 | 9 | 12 | 9 |
| SG&A | - | - | - | - | - | - | $2.61B | $2.90B | $2.64B | $2.57B | $2.38B | $2.76B | $2.27B | $2.34B | $2.60B | $1.85B | $2.27B | $2.74B | $2.31B | $2.46B | $2.38B | $2.73B | $2.31B | $2.51B | $2.70B | $2.31B | $2.57B | $2.48B | $2.60B | $2.27B |
| Avg Forecast | $3.19B | $2.68B | $2.42B | $2.95B | $3.08B | $2.68B | $2.20B | $2.91B | $2.26B | $2.44B | $2.00B | $2.65B | $2.05B | $2.22B | $2.45B | $1.89B | $2.06B | $2.54B | $2.31B | $2.60B | $2.19B | $2.81B | $2.02B | $2.44B | $3.01B | $2.22B | $2.64B | $2.30B | $2.56B | $1.71B |
| High Forecast | $3.22B | $2.74B | $2.90B | $3.05B | $3.14B | $3.22B | $2.64B | $3.50B | $2.71B | $2.93B | $2.40B | $3.18B | $2.46B | $2.66B | $2.94B | $2.27B | $2.47B | $3.05B | $2.77B | $3.12B | $2.62B | $3.38B | $2.42B | $2.92B | $3.61B | $2.66B | $3.16B | $2.76B | $3.08B | $2.05B |
| Low Forecast | $3.12B | $2.62B | $1.94B | $2.86B | $3.03B | $2.15B | $1.76B | $2.33B | $1.81B | $1.95B | $1.60B | $2.12B | $1.64B | $1.77B | $1.96B | $1.51B | $1.64B | $2.03B | $1.85B | $2.08B | $1.75B | $2.25B | $1.61B | $1.95B | $2.41B | $1.77B | $2.11B | $1.84B | $2.05B | $1.36B |
| Surprise % | - | - | - | - | - | - | 1.19% | 0.99% | 1.17% | 1.06% | 1.19% | 1.04% | 1.10% | 1.05% | 1.06% | 0.98% | 1.10% | 1.08% | 1.00% | 0.95% | 1.09% | 0.97% | 1.14% | 1.03% | 0.90% | 1.04% | 0.97% | 1.08% | 1.02% | 1.33% |
Sanofi's average Quarter SG&A projection for Jun 23 is $2.68B, based on 19 Wall Street analysts, with a range of $2.15B to $3.22B. The forecast indicates a 2.93% rise compared to SNY last annual SG&A of $2.61B (Mar 23).
Sanofi EPS Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Dec 17 | Sep 17 | Jun 17 | Mar 17 | Dec 16 | Sep 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 2 | 1 | 3 | 5 | 19 | 16 | 20 | 19 | 14 | 9 | 18 | 19 | 10 | 10 | 16 | 16 | 7 | 14 | 17 | 14 | 12 | 19 | 12 | 18 | 12 | 20 | 9 | 12 | 9 |
| EPS | - | - | - | - | - | - | $0.80 | $0.58 | $0.83 | $0.47 | $0.81 | $0.45 | $0.93 | $0.48 | $0.43 | $0.78 | $3.03 | $-0.01 | $0.70 | $-0.03 | $0.46 | $0.10 | $0.91 | $0.31 | $0.05 | $0.63 | $0.41 | $2.26 | $0.31 | $0.65 |
| Avg Forecast | $1.25 | $0.83 | $0.86 | $0.86 | $1.30 | $0.83 | $0.80 | $0.74 | $1.20 | $0.79 | $0.71 | $0.64 | $0.91 | $0.63 | $0.53 | $0.95 | $0.52 | $0.56 | $0.88 | $0.65 | $0.61 | $0.56 | $0.71 | $0.60 | $0.67 | $0.78 | $0.68 | $0.61 | $0.62 | $0.53 |
| High Forecast | $1.30 | $0.86 | $0.89 | $0.97 | $1.64 | $1.00 | $0.97 | $0.90 | $1.43 | $0.95 | $0.86 | $0.78 | $1.09 | $0.76 | $0.64 | $1.13 | $0.63 | $0.68 | $1.05 | $0.78 | $0.74 | $0.67 | $0.86 | $0.72 | $0.80 | $0.93 | $0.82 | $0.73 | $0.74 | $0.64 |
| Low Forecast | $1.18 | $0.81 | $0.84 | $0.82 | $0.79 | $0.67 | $0.63 | $0.59 | $0.96 | $0.63 | $0.57 | $0.51 | $0.73 | $0.51 | $0.42 | $0.76 | $0.42 | $0.45 | $0.70 | $0.52 | $0.49 | $0.45 | $0.57 | $0.48 | $0.53 | $0.63 | $0.54 | $0.49 | $0.50 | $0.43 |
| Surprise % | - | - | - | - | - | - | 1.00% | 0.78% | 0.69% | 0.59% | 1.14% | 0.70% | 1.01% | 0.77% | 0.81% | 0.82% | 5.79% | -0.01% | 0.81% | -0.05% | 0.74% | 0.18% | 1.28% | 0.51% | 0.08% | 0.80% | 0.60% | 3.73% | 0.50% | 1.22% |
According to 19 Wall Street analysts, Sanofi's projected average Quarter EPS for Jun 23 is $0.83, with a low estimate of $0.67 and a high estimate of $1.00. This represents a 4.30% increase compared to SNY previous annual EPS of $0.80 (Mar 23).
Sanofi Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| GSK | GSK | $43.01 | $58.00 | 34.85% | Hold |
| BMY | Bristol-Myers Squibb Company | $49.13 | $65.43 | 33.18% | Hold |
| MRK | Merck | $115.86 | $127.74 | 10.25% | Buy |
| AZN | AstraZeneca | $78.27 | $84.33 | 7.74% | Buy |
| JNJ | Johnson & Johnson | $165.52 | $176.29 | 6.51% | Buy |
| SNY | Sanofi | $57.13 | $57.36 | 0.40% | Buy |
| NVS | Novartis | $115.66 | $115.67 | 0.01% | Hold |
| GILD | Gilead Sciences | $82.81 | $80.00 | -3.39% | Buy |
| AMGN | Amgen | $332.45 | $286.95 | -13.69% | Buy |
| ABBV | AbbVie | $194.21 | $167.54 | -13.73% | Buy |
SNY Forecast FAQ
Is Sanofi a good buy?
Yes, according to 5 Wall Street analysts, Sanofi (SNY) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of SNY's total ratings.
What is SNY's price target?
Sanofi (SNY) average price target is $57.36 with a range of $48.07 to $64, implying a 0.40% from its last price of $57.13. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Sanofi stock go up soon?
According to Wall Street analysts' prediction for SNY stock, the company can go up by 0.40% (from the last price of $57.13 to the average price target of $57.36), up by 12.03% based on the highest stock price target, and down by -15.86% based on the lowest stock price target.
Can Sanofi stock reach $90?
SNY's average twelve months analyst stock price target of $57.36 does not support the claim that Sanofi can reach $90 in the near future.
What is Sanofi's current price target trend?
1 Wall Street analyst forecast a $64 price target for Sanofi (SNY) this month, up 12.03% from its last price of $57.13. Compared to the last 3 and 12 months, the average price target increased by 8.52% and increased by 4.45%, respectively.
What are Sanofi's analysts' financial forecasts?
SNY's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $48.19B (high $53.56B, low $42.86B), average EBITDA is $13.15B (high $14.35B, low $11.97B), average net income is $8.65B (high $10.41B, low $6.6B), average SG&A $10.91B (high $12.04B, low $9.79B), and average EPS is $3.8 (high $4.57, low $2.91).
Did the SNY's actual financial results beat the analysts' financial forecasts?
Based on Sanofi's last annual report (Dec 2022), the company's revenue was $45.39B, which missed the average analysts forecast of $47.63B by -4.70%. Apple's EBITDA was $13.77B, beating the average prediction of $9.9B by 39.10%. The company's net income was $6.72B, beating the average estimation of $6.46B by 4.09%. Apple's SG&A was $10.49B, beating the average forecast of $9.61B by 9.15%. Lastly, the company's EPS was $3.35, missing the average prediction of $3.45 by -2.85%. In terms of the last quarterly report (Mar 2023), Sanofi's revenue was $10.86B, missing the average analysts' forecast of $11.03B by -1.51%. The company's EBITDA was $3.38B, beating the average prediction of $2.66B by 27.15%. Sanofi's net income was $2B, beating the average estimation of $1.86B by 7.42%. The company's SG&A was $2.61B, beating the average forecast of $2.2B by 18.54%. Lastly, the company's EPS was $0.8, missing the average prediction of $0.8 by -0.00%